SCHEMBL5951394

SCHEMBL5951394

CC1=C(C)C(Cl)([SiH2]C2(Cl)C(C)=C(C)c3c(-c4ccc(C(C)(C)C)cc4)cccc32)c2cccc(-c3ccc(C(C)(C)C)cc3)c21.[Zr]

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320533 0.88 PDK2 (0.33) PARP1
SCHEMBL14645608 0.86 BRD4 (0.30) BRD4CREBBP
SCHEMBL6464431 0.85 PDCD1 (0.33)
SCHEMBL1531948 0.85 PDCD1 (0.33)
SCHEMBL1775470 0.82 PDCD1 (0.33)
SCHEMBL4061870 0.79 SLC6A2 (0.32)
SCHEMBL4064323 0.78 HDAC4 (0.38)
SCHEMBL4063173 0.77 GABRA1 (0.33)
SCHEMBL5951511 0.75 PDK2 (0.31)
SCHEMBL4066876 0.72 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807655-B2 Catalysts BOREALIS AG (AT) 2023-11-07 US disclosed
EP-3786195-B1 NOVEL TRANSITION METAL COMPOUND AND METHOD FOR PREPARING POLYPROPYLENE USING THE SAME LG CHEMICAL LTD (KR) 2023-08-02 EP disclosed
US-11370851-B2 Transition metal compound and method for preparing polypropylene using the same LG CHEM, LTD. 2022-06-28 US disclosed
EP-3768735-B1 CATALYSTS FOR OLEFIN POLYMERIZATION BOREALIS AG (AT) 2021-12-29 EP disclosed
EP-3562831-B1 CATALYSTS BOREALIS AG (AT) 2021-10-20 EP disclosed
US-20210189025-A1 Novel Transition Metal Compound and Method for Preparing Polypropylene Using the Same LG CHEM, LTD. (KR) 2021-06-24 US disclosed
EP-3786195-A1 NOVEL TRANSITION METAL COMPOUND AND METHOD FOR PREPARING POLYPROPYLENE USING SAME LG CHEM, LTD. (KR) 2021-03-03 EP disclosed
EP-3562831-A1 CATALYSTS Borealis AG (AT) 2019-11-06 EP disclosed
WO-2018122134-A1 CATALYSTS BOREALIS AG (AT) 2018-07-05 WO disclosed
US-7038070-B2 Preparation of preparing substituted indanones BASELL POLYOLEFINE GMBH (DE) 2006-05-02 US disclosed
EP-0968158-B1 METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM BASELL POLYOLEFINE GMBH (DE) 2005-08-10 EP disclosed
US-20050033076-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2005-02-10 US disclosed
US-20030009046-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2003-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370851-B2 Transition metal compound and method for preparing polypropylene using the same PPOX, PMS2, HMBS BRD4 4047/4885CREBBP 3846/4885PARP1 836/4885
US-11807655-B2 Catalysts SOD1, MT-CO2, MT-CO1 BRD4 3030/4885CREBBP 2606/4885PARP1 1440/4885
US-20210189025-A1 Novel Transition Metal Compound and Method for Preparing Polypropylene Using the Same PPOX, PMS2, HMBS BRD4 4046/4885CREBBP 3852/4885PARP1 1037/4885
US-20050033076-A1 Preparation of preparing substituted indanones CYP1A2, CYP2J2, IDH3A BRD4 3097/4885CREBBP 2331/4885PARP1 2362/4885
US-20030009046-A1 Preparation of preparing substituted indanones CYP1A2, CYP1B1, CYP1A1 BRD4 3045/4885CREBBP 2466/4885PARP1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.